Aerovate Therapeutics, Inc. - Total Utang marang Modal AVTE

Aerovate Therapeutics (AVTE) is developing treatments for pulmonary hypertension, relying on external financing due to a lack of recurring revenue. Management has demonstrated accountability by promptly closing loss-making tests to preserve capital. The business is currently revising its plans following the failure of key trials. This chart of the asset's value shows a total debt-to-equity ratio of 0.00.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the issuer's bankruptcy risk. By analyzing the dynamics of the debt-to-equity ratio, an investor assesses the stability of Aerovate Therapeutics (AVTE), whose biopharmaceutical operations for treating pulmonary hypertension do not depend on GDP cycles but instead rely on the success of clinical trials.